The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology

被引:13
作者
Virani, Salim S. [1 ,2 ,3 ]
Aspry, Karen [4 ,5 ]
Dixon, Dave L. [6 ]
Ferdinand, Keith C. [7 ]
Heidenreich, Paul A. [8 ]
Jackson, Elizabeth J. [9 ]
Jacobson, Terry A. [10 ]
McAlister, Janice L. [11 ]
Neff, David R.
Gulati, Martha
Ballantyne, Christie M. [1 ]
机构
[1] Baylor Coll Med, Houston, TX USA
[2] Michael E DeBakey VA Med Ctr, Houston, TX USA
[3] Aga Khan Univ, Karachi, Pakistan
[4] Brown Univ, Lifespan Cardiovasc Inst, Providence, RI USA
[5] Brown Univ, Alpert Med Sch, Providence, RI USA
[6] Virginia Commonwealth Univ, Sch Pharm, Richmond, VA USA
[7] Tulane Univ, Sch Med, New Orleans, LA USA
[8] Stanford Univ, Palo Alto, CA USA
[9] CardioTexas, Austin, TX USA
[10] Emory Univ, Sch Med, Atlanta, GA USA
[11] Piedmont Heart Inst, Atlanta, GA USA
关键词
Cardiovascular disease; LDL Cholesterol; Risk factors; Blood pressure; Lipoprotein modifying; Statins; BLOOD-PRESSURE; STATIN THERAPY; TREATMENT INTENSIFICATION; CARDIOVASCULAR-DISEASE; SECONDARY PREVENTION; LOWERING TREATMENT; LDL CHOLESTEROL; RISK; METAANALYSIS; MANAGEMENT;
D O I
10.1016/j.jacl.2023.02.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Despite the established role of low-density lipoprotein cholesterol (LDL-C) as a major risk factor for cardiovascular disease (CVD), and the persistence of CVD as the leading cause of morbidity and mortality in the United States, national quality assurance metrics no longer include LDL-C measurement as a required performance metric. This clinical perspective reviews the history of LDL-C as a quality and performance metric and the events that led to its replacement. It also presents patient, healthcare provider, and health system rationales for re-establishing LDL-C measurement as a performance measure to improve cholesterol control in high-risk groups and to stem the rising tide of CVD morbidity and mortality, cardiovascular care disparities, and related healthcare costs.(c) 2023 Published by Elsevier Inc. on behalf of National Lipid Association.This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页码:208 / 218
页数:11
相关论文
共 7 条
  • [1] The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint clinical perspective from the National Lipid Association and the American Society for Preventive Cardiology
    Virani, Salim S.
    Aspry, Karen
    Dixon, Dave L.
    Ferdinand, Keith C.
    Heidenreich, Paul A.
    Jackson, Elizabeth J.
    Jacobson, Terry A.
    McAlister, Janice L.
    Neff, David R.
    Gulati, Martha
    Ballantyne, Christie M.
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 13
  • [2] Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry
    Nanna, Michael G.
    Navar, Ann Marie
    Wang, Tracy Y.
    Li, Shuang
    Viral, Salim S.
    Li, Zhuokai
    Robinson, Jennifer G.
    Roger, Veronique L.
    Wilson, Peter W. F.
    Goldberg, Anne C.
    Koren, Andrew
    Louie, Michael J.
    Peterson, Eric D.
    AMERICAN HEART JOURNAL, 2019, 214 : 113 - 124
  • [3] Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012
    Wong, Nathan D.
    Young, Daphnee
    Zhao, Yanglu
    Huy Nguyen
    Caballes, Jared
    Khan, Irfan
    Sanchez, Robert J.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 (05) : 1109 - 1118
  • [4] Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry)
    Spinler, Sarah A.
    Cziraky, Mark J.
    Willey, Vincent J.
    Tang, Fengming
    Maddox, Thomas M.
    Thomas, Tyan
    Duenas, Gladys G.
    Virani, Salim S.
    AMERICAN JOURNAL OF CARDIOLOGY, 2015, 116 (04) : 547 - 553
  • [5] Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India
    Puri, Raman
    Mehta, Vimal
    Duell, P. Barton
    Nair, Devaki
    Mohan, Jagdish Chander
    Yusuf, Jamal
    Dalal, Jamshed J.
    Mishra, Sundeep
    Kasliwal, Ravi R.
    Agarwal, Rajeev
    Mukhopadhyay, Saibal
    Wardhan, Harsh
    Khanna, Narendra Nath
    Pradhan, Akshaya
    Mehrotra, Rahul
    Kumar, Amit
    Puri, Sonika
    Muruganathan, Arumugam
    Sattur, Gururaj Balvantrao
    Yadav, Madhur
    Singh, Harinder Pal
    Agarwal, Rajesh Kumar
    Nanda, Rashmi
    JOURNAL OF CLINICAL LIPIDOLOGY, 2020, 14 (02) : E1 - E13
  • [6] To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis
    Karlson, Bjorn W.
    Palmer, Michael K.
    Nicholls, Stephen J.
    Lundman, Pia
    Barter, Philip J.
    ATHEROSCLEROSIS, 2015, 241 (02) : 450 - 454
  • [7] Association between low maternal low-density lipoprotein cholesterol levels in the second trimester and delivery of small for gestational age infants at term: a case-control study of the national center for child health and development birth cohort
    Serizawa, Kana
    Ogawa, Kohei
    Arata, Naoko
    Ogihara, Atsushi
    Horikawa, Reiko
    Sakamoto, Naoko
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2017, 30 (12) : 1383 - 1387